Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

QUANTRO is on the move
October 2020
SHARING OPTIONS:

VIENNA—QUANTRO Therapeutics GmbH reported earlier this summer that it had begun operations with seed financing from the Boehringer Ingelheim Venture Fund (BIVF) and Evotec. QUANTRO's focus will be on combining and leveraging functional genetics and transcriptomics technologies to develop a drug discovery pipeline that will advance cell-based compound screens. The company is aiming to expand therapeutic options for several therapeutic and disease targets, one of which is blocking the activity of oncogenic transcription factors. In conjunction with the financing, BIVF and Evotec have acquired equal minority stakes in QUANTRO and will be represented on the company's supervisory board. In addition, Evotec will provide QUANTRO with hit identification services for its antitumor projects.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.